|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
| Mike Hurst at Baxa Corporation reviews the history of enteral feeding tube to IV line misconnections, and argues that the time is right for change
The recognition that IV and non-IV drugs should be administered in separate devices is supported by documentation of wrong-route medication errors in medical journal articles dating back to the late 1960s. The problem of misconnections, particularly enteral and breast milk being injected intravenously into neonates, still happens to this day despite warnings from virtually every affiliated professional and regulatory agency. This article argues that hospitals should do a top-to-bottom assessment of whether their systems can absolutely prevent non- IV fluid tubing from being misconnected to IV lines and take the appropriate measures to correct any deficiencies.
HISTORY
Journal articles dating back to the late 1960s and early 1970s discuss the issue of wrong-route medication errors. In the years since, many articles have been written on medical errors related to tubing misconnections. The Institute for Safe Medication Practices (1), for example, has written about oral to IV misconnections more than a dozen times since its inception in 1994. ISMP and other organisations have long advocated the use of non-luer connectors for administration of any nonparenteral drugs in order to prevent the possibility of an IV infusion of a non-sterile medication. Advocates for a new standard for enteral feeding include the Joint Commission on Hospital Accreditation (Joint Commission), which audits health systems for compliance to best practices, and the National Health Service (NHS) in the UK. |
Read full article from PDF >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Mike Hurst, RPh, MBA, is Vice President, Infusion Systems at Baxa Corporation. A national expert on
syringe pump intermittent IV infusion technology, Mike successfully managed the Swedish Medical Center
pharmacy in Seattle, and has 10 years’ experience as a pharmaceutical industry consultant. He developed
dilution, compounding, drug solution expiration tables and IV pharmacy operational recommendations that
set the standard for the most common intermittent syringe infusers. At Baxa, Mike has developed the Rapid
Rate Infuser – the standard for Adenoscan infusion for cardiac stress monitoring. Currently, he supports
business development and pharmacy process improvement activities. Mike holds a BS in Pharmacy from
the University of Washington and an MBA from City University, Bellevue |
|
 |
 |
 |
|

 |
Industry Events |
 |
2012 BIO International Convention
18-21 June 2012, Boston, Massachusetts
Connect, partner and innovate at the 2012 BIO International Convention, June 18-21, Boston, Mass. Network with 15,000+ global biotech leaders in the BIO Business Forum, Exhibition and Programme.
More info >> |
|
 |
News and Press Releases |
 |
APTAR PHARMA’S PRESERVATIVE-FREE MULTIDOSE DISPENSER OSD CHOSEN FOR THE FIRST TIME FOR AN EYE CARE PRODUCT
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser (OSD) has found its first application for the treatment of dry eye with the launch of VISMED® MULTI. Aptar Pharma has worked closely with the Swiss-German based Eye Care specialist TRB Chemedica for improving patient safety, achieving dosing accuracy and maintaining product stability on the ophthalmic spray device.
More info >> |
|
|